Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries

[cafead]

via Sagimet Biosciences has eased the pain of investors who backed its IPO last year, reporting phase 2b data in metabolic-associated steatohepatitis (MASH) that sent its stock soaring. Yet, the 20% dropout rate in the drug arm and exclusion of patients from the analysis prompted questions from analysts.

article source